Skip to main content

Virnich Daniel's Form 4/A amendment

Amended

Starling Oncology, Inc. (DFPH) · filed Nov 22, 2022

Accession no.
0001799191-22-000054
Filed
Nov 22, 2022
Trade date
Nov 15, 2022
Filing delay
7 days
Rule 10b5-1 plan
Not on the form (before 2023)
Original filed
Nov 17, 2022

This filing lists 1 non-derivative transaction. Open-market sales total $7.65K. It was filed 7 days after the trade.

This amendment replaces 0001799191-22-000016 (filed Nov 17, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Virnich DanielCIK 0001891107Officer (President)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2022Common StockSSaleDisposed−3,767$2.03F2−$7,647.01233,484Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This Form 4/A amends and restates the reporting persons Form 4 originally filed on November 17, 2022 in the entirety. This Form 4/A is being filed to correct the reporting persons original Form 4 from Code D to Code S. The sales reported in the Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement.

F2

Price is the volume weighted average selling price of all sales by the Reporting Person on November 15, 2022 within a one-dollar range. Actual prices ranged from $2.025 to $2.028. The Reporting Person hereby undertakes to provide upon request of the Commission staff full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)